PRVB - Provention Bio: A Promising Small-Cap Immuno-Endocrinology Player For 2020
Today, we will see why Provention Bio (PRVB) is a promising pick in 2020.
Company overview
Provention Bio is on the cusp of transformation, from clinical stage-biopharmaceutical company to a commercial organization. The company is focused on upstream pathways in T cell or B cell biology to intercept and prevent immune-mediated diseases. The company aims to help patients before they suffer long-term tissue damage.
Provention Bio's lead asset, Teplizumab (PRV-031), can prove to be a paradigm change in T1D (type 1 diabetes). The company is also studying another investigational asset, PRV-1010, for the